GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Scaled Net Operating Assets

OncoCyte (STU:7OC0) Scaled Net Operating Assets : 0.17 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

OncoCyte's operating assets for the quarter that ended in Dec. 2023 was €60.03 Mil. OncoCyte's operating liabilities for the quarter that ended in Dec. 2023 was €47.28 Mil. OncoCyte's Total Assets for the quarter that ended in Sep. 2023 was €76.45 Mil. Therefore, OncoCyte's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.17.


OncoCyte Scaled Net Operating Assets Historical Data

The historical data trend for OncoCyte's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Scaled Net Operating Assets Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 0.79 0.72 0.12 0.14

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.29 0.34 0.31 0.17

Competitive Comparison of OncoCyte's Scaled Net Operating Assets

For the Diagnostics & Research subindustry, OncoCyte's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Scaled Net Operating Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where OncoCyte's Scaled Net Operating Assets falls into.



OncoCyte Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

OncoCyte's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(60.027-47.276)/94.486
=0.13

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=68.676 - 8.649
=60.027

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=49.907 - 2.021 - 0.61
=47.276

OncoCyte's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(60.027-47.276)/76.447
=0.17

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=68.676 - 8.649
=60.027

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=49.907 - 2.021 - 0.61
=47.276

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of OncoCyte's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (STU:7OC0) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines